Shares of Relmada Therapeutics Inc. (RLMD), a late-stage biotechnology company addressing diseases of the central nervous system, are down more than 50% from their 52-week high of $7.22, recorded in March of this year, and trade around $3.45.
The company's lead investigational program is REL-1017, a novel NMDA receptor channel blocker, being developed as an adjunctive treatment for major depressive disorder (MDD).
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.